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The data described herein is related to the article “Differential
Effects of Leucine Supplementation in Young and Aged Mice at the
Onset of Skeletal Muscle Regeneration” [1]. Aging is associated
with a decreased ability of skeletal muscle to regenerate following
injury. Leucine supplementation has been extensively shown, in
young subjects, to promote protein synthesis during regeneration;
however, the effects of leucine supplementation on the Akt/mTOR
pathway in aged mice at the onset of muscle regeneration are not
fully elucidated. In this article, we present data on the Akt/mTOR
protein synthesis pathway at the onset of muscle regeneration in
young and aged C57BL/6J mice that are and are not receiving
leucine supplementation. More speciﬁcally, protein content of total
Akt, mTOR, p70S6K and 4EBP-1 are presented. Additionally, we
provide relative (phosphorylated:total) protein content compar-
isons of these targets as they present themselves in young and
aged mice who have neither been injured nor received leucine
supplementation. Lastly, markers of atrophy (FoxO1/O3, MuRF-1,
Atrogin-1) are also reported in these young and aged control
groups.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
/j.mad.2016.05.007
uark.edu (T.A. Washington).
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ject areaSkeletal muscle, leucine supplementation, regeneration, agingype of data Graphs, images
ow data was
acquiredImmunoblotting, PCRata format Analyzed
xperimental
factorsThree-month and 24-month old female C57BL/6J mice received an intramuscular
injection of bupivacaine or PBS and were or were not given leucine
supplementation.xperimental
featuresYoung and aged female C57BL/6J mice received an intramuscular injection of PBS
or bupivacaine in the tibialis anterior. After the injection, mice were given or not
given leucine supplementation. Three days after the injection, mice were sacri-
ﬁced, and the tibialis anterior was isolated, weighed and prepared for
immunoblotting.ata source
locationUniversity of Arkansas, Fayetteville, Arkansasata accessibility All data are provided with this articleD
Value of the data
 The data provides age-induced alterations in protein degradation and synthesis markers which
gives further insight into the natural physiological changes that occur as a function of age.
 Provides data on the effects of leucine supplementation on Akt/mTOR signaling proteins at the
onset of skeletal muscle regeneration in an aged population which is valuable for future studies
examining later time points when regeneration should be resolved.
 This data will help other researchers determine the effectiveness of leucine supplementation for
promoting regeneration in an aged population.1. Data
Fig. 1 contains western blot data of p-Akt/Akt, p-mTOR/mTOR, p-p70s6k/p70s6K, and p-4EBP-1/
4EBP-1 in young and aged mice. Fig. 2 contains real time PCR data of FoxO1, FoxO3, MuRF-1, and
Atrogin-1 in young and aged mice. Figs. 3 and 4 contain western blot data of Akt, mTOR, p70s6K, and
4EBP-1 at the onset of skeletal muscle regeneration with or without leucine supplementation in
young and aged mice, respectively.2. Experimental design, materials and methods
2.1. Experimental design
Female C57BL/6J mice were raised to 3 months or 24 months of age and were injected with either
0.03 mL of phosphate buffered solution (PBS) or 0.75% bupivacaine (Marcaine) in the belly of the
tibialis anterior (TA). After being injected, PBS- and bupivacaine-injected mice received leucine-
infused water (1.5 g/100 mL) or normal drinking water [2,3]. In total, both young and aged mice were
divided into the following four groups: 1) no leucine/uninjured (n ¼ 6); 2) no leucine/injured (n ¼ 6);
3) leucine uninjured (n ¼ 6); 4) leucine/uninjured (n ¼ 6).
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Fig. 1. The effect of age on markers of protein synthesis in uninjured, untreated mice. A) p-Akt:Akt B) p-mTOR:mTOR
C) p-p70S6K:p70S6K D) p-4EBP-1:4EBP-1 E) Representative blots of phosphorylated and total protein for each target. Sig-
niﬁcant difference is indicated by “*”. Pr0.05.
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Fig. 2. The effect of age on markers of protein degradation in uninjured, untreated mice. A) FoxO1:GAPDH B) FoxO3:GAPDH
C) MuRF-1:GAPDH D) Atrogin-1:GAPDH. Signiﬁcant difference is indicated by “*”. Pr0.05.
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Three days post-injection, the TA and tibias were extracted as previously described [1,4,6]. The TA
was snap frozen in liquid nitrogen and stored at 80 °C. Immediately following tissue harvest, the
mouse was euthanized via exsanguination of the heart.2.3. Immunoblotting analyses
Western blot analysis was performed as previously described [1,4,5]. Equal amounts of protein
were loaded into 8-12% SDS-PAGE gels, subjected to electrophoresis, and transferred to a PVDF
membrane. Blocked membranes were incubated with the following primary antibodies: p-Akt
(Ser473), Akt, p-mTOR (Ser2448), mTOR, p-p70S6K (Thr389), p70S6K, p-4E-BP1 (Thr37/46), and 4E-
BP1 (Cell Signaling, Danvers, MA). Anti-rabbit (7074) and anti-mouse (7076) secondary antibodies
(Cell Signaling, Danvers, MA) were diluted 1:1000 to 1:2000 in 5% BSA or non-fat milk, in TBST, and
incubated at room temperature for 1 h. Protein bands were detected with Enhanced Chemilumi-
nescence (ECL) and the Fluorochem M Imager (Protein Simple, Santa Clara, California). The Ponceau-
stained membranes were digitally scanned. The 45-kDa actin bands were quantiﬁed by densitometry
and used as a protein loading correction factor for each lane as previously described [4–6].
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Fig. 3. Total content of targets in the Akt/mTOR protein synthesis pathway in young mice at the onset of skeletal muscle
regeneration. A) Akt B) mTOR C) p70S6K D) 4E-BP-1 E) Representative Blot. Main effect of injury is indicated by “ME Injury”,
main effect of leucine is indicated by “ME Leucine”, and differences between groups are indicated by bars. Pr0.05.
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Fig. 4. Total content of targets in the Akt/mTOR protein synthesis pathway in aged mice at the onset of skeletal muscle
regeneration. A) Akt B) mTOR C) p70S6K D) 4E-BP-1 E) Representative Blot. Main effect of injury is indicated by “ME Injury”,
and a main effect of leucine is indicated by “ME Leucine”. Pr0.05.
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RNA was extracted with Trizol reagent (Life Technologies, Grand Island, NY, USA) and reverse tran-
scribed to cDNA as previously described [1,4,5,7]. Real-time PCR was performed and results were ana-
lyzed using the StepOne Real-Time PCR detection system (Applied Biosystems, Foster City, CA). Com-
mercially available Taqman probes (Applied Biosystems, Foster City, CA) were used for the following gene
targets: FoxO1 (FAM), FoxO3 (FAM), MuRF-1 (FAM), Atrogin-1 (FAM), GAPDH (FAM). Cycle threshold (Ct)
was determined and ﬁnal quantiﬁcation of gene expression was calculated using the ΔΔCt method {Ct
¼ [ΔCt(calibrator) – ΔCt(sample)]}. Relative quantiﬁcation was then calculated as 2ΔΔCt.
2.5. Statistical analyses
Results are reported as mean 7SE. Pre-planned comparison between 3 month and 24 month
uninjured, untreated controls (no injury, no leucine) were conducted by Student's t-tests. Two-way
ANOVAs (leucine supplementation  injury) were conducted at each level of age to determine sig-
niﬁcant main effects and interactions (CA, SPSS 23). Post hoc analysis on signiﬁcant interactions was
done with a Student–Newman–Keuls test. Signiﬁcance was established at an alpha level of 0.05.Funding
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